000266800 001__ 266800
000266800 005__ 20240121002250.0
000266800 0247_ $$2pmc$$apmc:PMC10776839
000266800 0247_ $$2doi$$a10.1038/s41531-023-00605-x
000266800 0247_ $$2pmid$$apmid:38195715
000266800 0247_ $$2altmetric$$aaltmetric:158273185
000266800 037__ $$aDZNE-2024-00052
000266800 041__ $$aEnglish
000266800 082__ $$a610
000266800 1001_ $$0P:(DE-2719)9001473$$aFrank, Anika$$b0$$eFirst author
000266800 245__ $$aSerum neurofilament indicates accelerated neurodegeneration and predicts mortality in late-stage Parkinson's disease.
000266800 260__ $$aLondon [u.a.]$$bNature Publ. Group$$c2024
000266800 3367_ $$2DRIVER$$aarticle
000266800 3367_ $$2DataCite$$aOutput Types/Journal article
000266800 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1705504485_18424
000266800 3367_ $$2BibTeX$$aARTICLE
000266800 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000266800 3367_ $$00$$2EndNote$$aJournal Article
000266800 520__ $$aDifferent stages of Parkinson's disease (PD) are defined by clinical criteria, while late-stage PD is marked by the onset of morbidity milestones and rapid clinical deterioration. Based on neuropathological evidence, degeneration in the dopaminergic system occurs primarily in the early stage of PD, raising the question of what drives disease progression in late-stage PD. This study aimed to investigate whether late-stage PD is associated with increased neurodegeneration dynamics rather than functional decompensation using the blood-based biomarker serum neurofilament light chain (sNfL) as a proxy for the rate of neurodegeneration. The study included 118 patients with PD in the transition and late-stage (minimum disease duration 5 years, mean (SD) disease duration 15 (±7) years). The presence of clinical milestones (hallucinations, dementia, recurrent falls, and admission to a nursing home) and mortality were determined based on chart review. We found that sNfL was higher in patients who presented with at least one clinical milestone and increased with a higher number of milestones (Spearman's ρ = 0.66, p < 0.001). Above a cutoff value of 26.9 pg/ml, death was 13.6 times more likely during the follow-up period (95% CI: 3.53-52.3, p < 0.001), corresponding to a sensitivity of 85.0% and a specificity of 85.7% (AUC 0.91, 95% CI: 0.85-0.97). Similar values were obtained when using an age-adjusted cutoff percentile of 90% for sNfL. Our findings suggest that the rate of ongoing neurodegeneration is higher in advanced PD (as defined by the presence of morbidity milestones) than in earlier disease stages. A better understanding of the biological basis of stage-dependent neurodegeneration may facilitate the development of neuroprotective means.
000266800 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000266800 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000266800 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000266800 7001_ $$aBendig, Jonas$$b1
000266800 7001_ $$00000-0002-0870-8105$$aSchnalke, Nils$$b2
000266800 7001_ $$aKlingelhoefer, Lisa$$b3
000266800 7001_ $$aReichmann, Heinz$$b4
000266800 7001_ $$aAkgün, Katja$$b5
000266800 7001_ $$aZiemssen, Tjalf$$b6
000266800 7001_ $$0P:(DE-2719)2814178$$aFalkenburger, Björn H$$b7$$eLast author$$udzne
000266800 773__ $$0PERI:(DE-600)2819218-7$$a10.1038/s41531-023-00605-x$$gVol. 10, no. 1, p. 14$$n1$$p14$$tnpj Parkinson's Disease$$v10$$x2373-8057$$y2024
000266800 8564_ $$uhttps://pub.dzne.de/record/266800/files/DZNE-2024-00052.pdf$$yOpenAccess
000266800 8564_ $$uhttps://pub.dzne.de/record/266800/files/DZNE-2024-00052.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000266800 909CO $$ooai:pub.dzne.de:266800$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000266800 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001473$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000266800 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814178$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000266800 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000266800 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000266800 9141_ $$y2024
000266800 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-29
000266800 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-29
000266800 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-29
000266800 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000266800 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNPJ PARKINSONS DIS : 2022$$d2023-08-29
000266800 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:11:33Z
000266800 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:11:33Z
000266800 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-29
000266800 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-29
000266800 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-29
000266800 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000266800 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:11:33Z
000266800 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-29
000266800 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNPJ PARKINSONS DIS : 2022$$d2023-08-29
000266800 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-29
000266800 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-29
000266800 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-29
000266800 9201_ $$0I:(DE-2719)1710012$$kAG Falkenburger$$lTranslational Parkinson Research$$x0
000266800 9201_ $$0I:(DE-2719)1710001$$kAG Kempermann$$lAdult Neurogenesis$$x1
000266800 980__ $$ajournal
000266800 980__ $$aVDB
000266800 980__ $$aUNRESTRICTED
000266800 980__ $$aI:(DE-2719)1710012
000266800 980__ $$aI:(DE-2719)1710001
000266800 9801_ $$aFullTexts